Sign in
Not yet taking people in United StatesEarly phase 1

How immunotherapy cancer drugs affect the way the liver handles other medicines

Tests whether immunotherapy changes how the liver processes other drugs in adults with cancer.

Key facts

Who runs it
Indiana University
Where
Indianapolis, United StatesSee the site
Trial code
Registry title
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Status
Not yet recruiting
Phase
Early phase 1
People taking part
80 people, planned
Started
Sept 2026
Expected to end
Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • ICI Therapy
Record updated
15 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer who are starting treatment that includes an immune checkpoint inhibitor. It studies whether these drugs change how the liver processes other drugs.

Age
18 years or older
Sex
All sexes can join
Disease stage
Diagnosed with cancer, about to start treatment that includes an immune checkpoint inhibitor (for example atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab).
Earlier treatment
Cannot be taking systemic immunosuppressant drugs, or probe cocktail drugs and strong inhibitors or inducers of the relevant CYP enzymes or drug transporters. They can re-screen after stopping these for 7 days or more before Study Visit 1.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Body weight under 50 kg (110 lb) or BMI over 35, or hemoglobin under 10 g/dL
  • Chronic liver or kidney disease, or abnormal liver or kidney test results
  • Autoimmune disorder, such as lupus, Crohn's disease or multiple sclerosis
  • Allergy to a study drug, a current infection needing treatment, or unable to take oral medication

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • ≥ 18 years old at the time of informed consent
  • Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)
  • Ability to provide written informed consent and HIPAA authorization

Who cannot take part

  • Poor performance status that makes it unlikely the patient will complete 3 cycles of immune checkpoint inhibitor (at the treating oncologist's discretion)
  • Concomitant treatment with systemic immunosuppressant drugs (see Appendix 3 for list); Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
  • Concomitant treatment with a CYP/transporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list); Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
  • Are unwilling/unable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study
  • Inability to take oral medication
  • Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated glomerular filtration rate <45 mL/minute/1.73 m2 BSA; Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)
  • Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis
  • History of intolerance, allergic reaction, or hypersensitivity to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)
  • Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)
  • Low baseline hemoglobin, defined as <10 g/dL; Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)
  • Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or aspartate aminotransferase >96 U/L, alanine aminotransferase > 80 IU/L, alkaline phosphatase >260 U/L, or total bilirubin > 2.6 mg/dL; Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)
  • Actively pregnant or breastfeeding
  • Body weight less than 50 kg or a BMI >35

Where in United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United StatesContact: Ross RobinsonNot yet recruiting

About the trial

What the trial wants to find out

Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.

The 2 groups in the trial

  • Cohort 1Treatment being tested

    CYP enzyme/drug transporter probe substrates administered at two study visits: one before initiation of ICI therapy and one while on therapy.

    Treatment: ICI Therapy

  • Cohort 2Treatment being tested

    CYP enzyme/drug transporter probe substrates administered at one study visit: during ICI therapy.

    Treatment: ICI Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Plain-language title
How immunotherapy cancer drugs affect the way the liver handles other medicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
15 July 2026